

## Wednesday, October 1

9:30-10:30 *Registration and welcome remarks*

### Opening lectures

- 10:40-11:20 **Keynote speaker: Rino Rappuoli**  
Biotechnopolo di Siena Foundation; IT  
*Strategies for pandemic preparedness.*
- 11:20-12:00 **Keynote speaker: Sergio Abrignani**  
INGM, National Institute of Molecular Genetics, Milano; IT  
*Functional interrogation of tissutal T Lymphocytes.*
- 12:00-13:30 *Lunch*

### Session 1

- 13:30-14:00 **Susan Pereira Ribeiro**  
Emory University, Atlanta; USA  
*TGF- $\beta$  mediates epigenetic control of innate antiviral responses and SIV reservoir size.*
- 14:00-14:20 Selected abstract for one oral presentation 20'
- 14:20-15:00 **Keynote speaker: Cecilia Garlanda**  
Humanitas, Milano; IT  
*Humoral Innate Immunity and Acute Phase Proteins in COVID-19.*
- 15:00-15:20 Selected abstract for one oral presentation 20'
- 15:20-15:50 **Carole Devaux**  
Luxembourg Institute of Health; LU  
*Exploiting innate immunity for targeted therapies against infectious diseases.*
- 15:50-16:10 Selected abstract for one oral presentation 20'
- 16:10-16:30 *Break*
- 16:30-17:10 **Keynote speaker: Felix Rey**  
Institute Pasteur, Paris; FR  
*A common antibody mechanism to block class II virus entry and plasmodium transmission.*

17:10-17:40	<b>Stephan Ruckdäschel</b> HealthEcon Ltd., Basel; CH <i><b>Challenging the value of medical innovation. Concept and application of Health Technology Assessment (HTA)</b></i>
19:00-	<b>Informal, standing dinner (Italian Pizza and drinks)</b>

## Thursday, October 2

### Session 2

9:00-9:30	<b>Registration</b>
9:30-10:00	<b>Sabine Suppmann</b> Fraunhofer ITMP-IIP, Penzberg; DE <i><b>Generation of Human Anti-YFV Monoclonal Antibodies from Booster Vaccinated Individuals.</b></i>
10:00-10:20	<b>Selected abstract for one oral presentation 20'</b>
10:20-10:40	<b>Break</b>
10:40-11:20	<b>Keynote speaker: Fausto Baldanti</b> Fondazione IRCCS Policlinico San Matteo, Pavia; IT <i><b>History of immunotherapy against infectious diseases.</b></i>
11:20-11:40	<b>Selected abstract for one oral presentation 20'</b>
11:40-12:10	<b>Mireia Pelegrin</b> IRMB-INSERM, Montpellier; FR <i><b>Antibody-based and CAR-T cell-based therapeutic approaches against SARS-CoV-2 infections.</b></i>
12:10-12:40	<b>Fabio Bagnoli</b> GSK, Siena; IT <i><b>Reverse development of vaccines against antimicrobial-resistant pathogens.</b></i>
12:40-14:30	<b>Lunch</b>
14:30-17:00	<b>POSTER SESSION</b>
19:00-	<b>Dinner</b>

## Friday, October 3

### Session 3

9:30-10:00

**Camilla Foged**

University of Copenhagen; DK

***Next-generation mRNA vaccines: new RNA modalities and delivery systems.***

10:00-10:20

**Selected abstract for one oral presentation 20'**

10:20-10:40

**Break**

10:40-11:20

**Keynote speaker: Davide Corti**

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona; CH

***Development of monoclonal antibodies for infectious diseases.***

11:20-11:50

**Luca Varani**

IRB, Institute for Research in Biomedicine, Bellinzona; CH

***Structure based rational design of neuroprotective antibodies against prion protein.***

12:50-13:30

**Lunch**

### Session 4

13:30-14:00

**Delphine Muriaux**

IRIM, Institut de Recherche en Infectiologie, Montpellier; FR

***Development of a Human Induced Pluripotent Stem Cell-Derived Bronchial Organoids to study SARS-CoV-2 infection and COPD differential innate immune responses to viral infections.***

14:00-14:20

**Selected abstract for one oral presentation 20'**

14:20-14:50

**Julia Garcia Prado**

IrsiCaixa, Badalona; ES

***Lymphoid organoids for the study of infectious diseases.***

### Closing lecture

14:50-15:30

**Keynote speaker: Antonio Lanzavecchia**

INGM; National Institute of Molecular Genetics, Milano; IT

15:30-16:00

***Conclusion and remarks***